Abstract
We evaluated the in vitro effects of IL-12, alone and in association with IL-2 on MDS bone marrow and peripheral blood cells. Thirty-six patients and 14 healthy subjects were studied. Natural killer-activity (NK-a) levels and lymphocyte immunophenotypes were determined in fresh bone marrow (BMMNC) and peripheral blood mononuclear cells (PBMNC), which then were resuspended in medium containing IL-2, IL-12 or IL-2 + IL-12 for 7 days. Re-evaluation of NK-a levels, lymphocyte immunophenotypes, clonogenic activity and cytokine release showed that, unlike IL-2, IL-12 did not significantly increase NK-a or CD3-/56+ cell levels in either bone marrow or peripheral blood; IL-2 + 12 led to a significant increase that fell between the values reached by each cytokine alone. IL-2 + 12 and, although to a lesser extent, also IL-12 alone induced the release of large amounts of γ-IFN and α-TNF. In addition, the number of clusters particularly decreased in the samples treated with IL-2 + 12 and IL-12 alone. Clonogenic activity was not modified after stimulation with any of the treatment. These data suggest that IL-12 induces the release of inhibitory cytokines in normal as well as MDS cells and that it could be used in patients with elevated bone marrow blastosis.
| Original language | English |
|---|---|
| Pages (from-to) | 1726-1731 |
| Number of pages | 6 |
| Journal | Leukemia |
| Volume | 11 |
| Issue number | 10 |
| Publication status | Published - 1997 |
Fingerprint
Keywords
- Clonogenic activity
- Interleukin-12
- Interleukin-2
- Myelodysplastic syndromes
- NK activity
ASJC Scopus subject areas
- Hematology
- Cancer Research
Cite this
In vitro effects of IL-12 and IL-2 on NK cells, cytokine release and clonogenic activity in myelodysplastic syndromes (MDS). / Sarina, B.; Cortelezzi, A.; Cattaneo, C.; Pomati, M.; Silvestris, I.; Di Stefano, M.; Lambertenghi-Deliliers, D.; Hu, C.; Monza, M.; Maiolo, A. T.
In: Leukemia, Vol. 11, No. 10, 1997, p. 1726-1731.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - In vitro effects of IL-12 and IL-2 on NK cells, cytokine release and clonogenic activity in myelodysplastic syndromes (MDS)
AU - Sarina, B.
AU - Cortelezzi, A.
AU - Cattaneo, C.
AU - Pomati, M.
AU - Silvestris, I.
AU - Di Stefano, M.
AU - Lambertenghi-Deliliers, D.
AU - Hu, C.
AU - Monza, M.
AU - Maiolo, A. T.
PY - 1997
Y1 - 1997
N2 - We evaluated the in vitro effects of IL-12, alone and in association with IL-2 on MDS bone marrow and peripheral blood cells. Thirty-six patients and 14 healthy subjects were studied. Natural killer-activity (NK-a) levels and lymphocyte immunophenotypes were determined in fresh bone marrow (BMMNC) and peripheral blood mononuclear cells (PBMNC), which then were resuspended in medium containing IL-2, IL-12 or IL-2 + IL-12 for 7 days. Re-evaluation of NK-a levels, lymphocyte immunophenotypes, clonogenic activity and cytokine release showed that, unlike IL-2, IL-12 did not significantly increase NK-a or CD3-/56+ cell levels in either bone marrow or peripheral blood; IL-2 + 12 led to a significant increase that fell between the values reached by each cytokine alone. IL-2 + 12 and, although to a lesser extent, also IL-12 alone induced the release of large amounts of γ-IFN and α-TNF. In addition, the number of clusters particularly decreased in the samples treated with IL-2 + 12 and IL-12 alone. Clonogenic activity was not modified after stimulation with any of the treatment. These data suggest that IL-12 induces the release of inhibitory cytokines in normal as well as MDS cells and that it could be used in patients with elevated bone marrow blastosis.
AB - We evaluated the in vitro effects of IL-12, alone and in association with IL-2 on MDS bone marrow and peripheral blood cells. Thirty-six patients and 14 healthy subjects were studied. Natural killer-activity (NK-a) levels and lymphocyte immunophenotypes were determined in fresh bone marrow (BMMNC) and peripheral blood mononuclear cells (PBMNC), which then were resuspended in medium containing IL-2, IL-12 or IL-2 + IL-12 for 7 days. Re-evaluation of NK-a levels, lymphocyte immunophenotypes, clonogenic activity and cytokine release showed that, unlike IL-2, IL-12 did not significantly increase NK-a or CD3-/56+ cell levels in either bone marrow or peripheral blood; IL-2 + 12 led to a significant increase that fell between the values reached by each cytokine alone. IL-2 + 12 and, although to a lesser extent, also IL-12 alone induced the release of large amounts of γ-IFN and α-TNF. In addition, the number of clusters particularly decreased in the samples treated with IL-2 + 12 and IL-12 alone. Clonogenic activity was not modified after stimulation with any of the treatment. These data suggest that IL-12 induces the release of inhibitory cytokines in normal as well as MDS cells and that it could be used in patients with elevated bone marrow blastosis.
KW - Clonogenic activity
KW - Interleukin-12
KW - Interleukin-2
KW - Myelodysplastic syndromes
KW - NK activity
UR - http://www.scopus.com/inward/record.url?scp=16944364153&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=16944364153&partnerID=8YFLogxK
M3 - Article
C2 - 9324294
AN - SCOPUS:16944364153
VL - 11
SP - 1726
EP - 1731
JO - Leukemia
JF - Leukemia
SN - 0887-6924
IS - 10
ER -